Trial | NCT00506805  Report issue

Title

Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies
A Phase 1, Open-label, Dose-escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies Or Non-Hodgkin's Lymphoma

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    snx-5422 ...

  • Study Participants

    44
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
Study Started
Jun 30
2007
Primary Completion
Mar 31
2010
Study Completion
Mar 31
2010
Last Update
May 28
2012
Estimate

Drug SNX-5422

dose escalated, tablets every other day; undetermined duration until disease progression

Single Arm Experimental

Criteria 

Inclusion Criteria:

>18 years old
histologically confirmed solid tumor malignancy
refractory to available therapy or for which no therapy is available
adequate organ function

Exclusion Criteria:

CNS malignancy
significant GI disease
at risk for prolonged QT interval
No Results Posted